Therapeutic effect of Jusvinza in patients with Rheumatoid Arthritis. Real world study
Keywords:
rheumatoid arthritis, immunoregulatory treatment, JusvinzaAbstract
Introduction The use of this innovative Cuban biotechnology product will contribute to improving the quality of medical care for patients with RA. Its availability has the potential to positively impact the health indicators of the population diagnosed with RA, specifically by reducing the number of patients with unfavorable disease outcomes.
Objective To compare the therapeutic effect of Jusvinza monotherapy with its combination with MTX in adult patients with moderate to severe clinical stage RA.
Method This was a prospective, single-center, open-label, uncontrolled clinical study. The sample consisted of 74 patients. summary measures were used for qualitative variables (percentages) and for quantitative variables (mean, median, standard deviation, interquartile range, maximum and minimum values). To compare means between two independent samples with normal distributions, the t-test and the Mann-Whitney U test for two independent means without normal distribution were used. A significance level of 0.05 was set for all hypothesis tests.
Results. The female sex prevailed 66 (89.2 %), the overall median for the age of the patients was 57 years. At 24 weeks in both groups, a decrease in the DAS 28 values that classify as disease in remission [monotherapy (2.53) / combined therapy (2.29)]. All patients achieved a EULAR response and expressed a clinical improvement of 20% (ACR 20); patients with a 70% improvement (ACR 70) predominated in the monotherapy group (26; 70.3% vs 25; 67.6%).
Conclusions Treatment with Jusvinza as monotherapy or in combination with MTX allows for a reduction in clinical activity in patients with moderate to severe RA. Jusvinza in both treatment groups was shown to be a drug that induces clinical remission and restoration of functional capacity in patients with RA.
Downloads
References
Firestein GS, Budd RC, Gabriel SE, Koretzky GA, McInnes IB and O`Dell JR. Kelly y Firestein. Tratado de reumatología. 11.ªed. Barcelona: Elsevier España; 2022.p.1236.
Alegre de Miquel C, Alegre Sancho JJ, Alonso Ruiz A, Alperi Lopez M, Alvarez Vega JL. et al. Tratado de Enfermedades Reumáticas de la SER. Madrid: Editorial Panamericana; 2018. p.394.
Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, Alpizar –Rodríguez D, Lauper K. Global Epidemiology of Rheumatoid Arthritis. Nat Rev Rheumatol. 2022; 18:591 -602. Disponible en: https://doi.org/10.1038/s41584-022-00827-y
Pons-Estel B, Gladar. Cohorte Latino Americana de pacientes con Artritis Reumatoide de reciente comienzo (ARRC). Grupo Latino Americano de Estudio de Artritis Reumatoide. Reumatología 2015; (21): 165.
Reyes Llerena GA, Guibert Toledano M, Hernández Martínez AA, González Otero ZA, Alcocer Varela J, Cardiel MH, et al. Prevalence of musculoskeletal complaints and disability in Cuba. A community-based study using the COPCORD core questionnaire. Clin Exp Rheumatol [Internet]. 2000 [citado 12 Nov 2023];18(6):739-42. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11138339/
Miguel Lavariega D, Elizararrás Rivas J, Baltiérrez Hoyos R, Velasco Tobón U, Vargas Daza E R, Galicia Rodríguez L. Perfil epidemiológico de la artritis reumatoide. Rev Med Inst Mex Seguro Soc. 2023; 61(5): 574-582. Disponible en: doi. 10.5281/zenodo.831627
Alonso Ruiz A, Alperi López M, Álvaro-Gracia Álvaro JM, Andreu Sánchez JL, Arboleya Rodríguez L, Balsa Criado A, et al. Manual SER de enfermedades reumáticas. Madrid, España: Editorial Elsevier; 2014.p.
Grupo de trabajo de la GUIPCAR. Guía de Práctica Clínica para el Manejo de Pacientes con Artritis Reumatoide. Madrid. Sociedad Española de Reumatología. 2019. [Internet] [citado 15 Dic 2023]. Disponible en: https://www.ser.es/wp-content/uploads/2019/03/Guia-de-Practica-Clinica-para-el-Manejo-de-Pacientes-con-Artritis- Reumatoide.pdf
Cervera R, Espinosa, G, Ramoa Casals, M., Hernández Rodríguez, J., Cid, M. En: Enfermedades autoinmune sistémicas. Diagnóstico y tratamiento. 6ªed: Editorial MédicaPanamericana; 2021. S.A. ISBN 9788491106524
Smolen JS, Landewé RB, Bijlsma J, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis [Internet]. 2020 [citado 15 Dic 2023]; 79(6):685-99. https://pubmed.ncbi.nlm.nih.gov/31969328/
Schneeberger EE, Acosta Felquer MA, Citera G, Soriano E, Mysler E. Persistencia a largo plazo de agentes biológicos en el tratamiento de pacientes con Artritis Reumatoidea: una revisión sistemática de la literatura. Rev. argent. reumatolg. [Internet]. 2020 Sep [citado 2022 Ene 18]; 31(3): 6-18. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S2362-36752020000300001&lng=es
Zhao SS, Kearsley-Fleet L, Bosworth A, Watson K; BSRBR-RA Contributors Group; Hyrich KL. Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis. Rheumatology (Oxford). 2022 Nov 28; 61(12): 4678-4686. doi: 10.1093/rheumatology/keac190. PMID: 35357421; PMCID: PMC9707051.
Pasquel Morán, N. S., Villacrés García, E. K., Cely Almeida, N. O, Yagual C. Uso de terapias biológicas en artritis reumatoide. RECIAMUC. 2021;5 (2):13-22. Disponible en. https://doi.org/10.26820/reciamuc/5.(2).
Prada D, Gómez J, Lorenzo N, Corrales O, López A, González E, et al. Phase I Clinical Trial with a Novel Altered Peptide Ligand Derived from Human Heat-Shock Protein 60 for Treatment of Rheumatoid Arthritis: Safety, Pharmacokinetics and Preliminary Therapeutic Effects. J Clin Trials [Internet]. 2018 [citado 15 Dic 2023];8:339. Disponible en: https://www.academia.edu/download/82904827/phase-i-clinical-trial-with-a-novel-altered-peptide-ligand-derived-fromhuman-heatshock-protein-60-for-treatment-of-rheumatoid-arth-2167-.pdf
RPCEC. Centro Nacional Coordinador de Ensayos Clínicos. Registro Público Cubano de Ensayos Clínicos. Ministerio de Salud Pública de Cuba. 2018 Disponible en https://rpcec.sld.cu/ensayos/RPCEC00000230-Sp.
Alba R, Muñoz R, Espinoza L, Khamashta M, Matucci-Cerinic M, Sanmartí R, editores. Enfermedades Inflamatorias Reumatológicas. Santo Domingo: Producciones Científicas Ltda [Internet]. 2016 [citado 5 Ene 2022]; 117-29.
Reyes Llerena GA, Panelo Coello A, Guibert Toledano M, Hernandez Martinez A, Lopez Aguilera IR, Fernández Mederos I, Taylor Jiménez B, Torres Moya R, et al. Validación de la versión cubana de la dimensión física del Cuestionario de Evaluación de Salud (HAQ) en cubanos con Artritis Reumatoide. (CU-HAQ). Rev. cuba. de Reumatol. [Internet].2002 [citado 12Oct 2024];4 (1). Disponible en: https://revreumatologia.sld.cu/index.php/reumatologoa/rticle/view/240
World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. JAMA. 2025 Jan 7; 333(1): 71-74. Disponible en: https://10.1001/jama.2024.21972.PMID:39425955.
CECMED. Regulación de Buenas Prácticas Clínicas. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/Reglamentacion/Res_MINSAP-165-00.pdf
.Takanashi S, Kaneko Y, Takeuchi T. CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice. Ann Rheum Dis. 2020 May; 79(5): 671-674. doi: 10.1136/annrheumdis-2019-216607. Everett S. 2022 American College of Rheumatology (ACR) Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2023 Aug; 75(8): 1629-1630. Disponible en: https://10.1002/acr.25119.
Prada Hernández DM. Centro Nacional Coordinador de Ensayos Clínicos. Registro Público Cubano de Ensayos Clínicos. Ministerio de Salud Pública de Cuba. [Internet] 31 Ago 2023 [citado 20 Jun 2025] Disponible en: https://rpcec.sld.cu/ensayos/RPCEC00000404-Sp.
Calisté Manzano O. Jusvinza en adultos con Artritis Reumatoide de las provincias orientales y Camagüey. Centro Nacional Coordinador de Ensayos Clínicos. Reg Púb Cub de Ens Clí. Ministerio de Salud Pública de Cuba. [Internet] Feb 2024 [citado 24 Jun 2025] Disponible en: https://rpcec.sld.cu/ensayos/RPCEC00000433-Sp.
Prada Hernández, Dinorah, Santana Hernández, I, Molinero Rodríguez, C, Gómez Morejón, J A, Milera Rodríguez, JM y Hernández Cuellar M V. Caracterización clínico-epidemiológica y tratamiento precoz en la artritis reumatoide temprana. Rev Cubana Reumatol [Internet]. 2012 [citado 29 Jun 2025];14(21):[aprox. 5 p.]. Disponible en: https://www.redalyc.org/articulo.oa?id=451644604004
Maranini B, Bortoluzzi A, Silvagni E, Govoni M. Focus on Sex and Gender: What We Need to Know in the Management of Rheumatoid Arthritis. J Pers Med. 2022 Mar 20; 12(3): 499. doi: 10.3390/jpm12030499. Koc GH, Looijen AEM, van der Horst-Bruinsma IE, de Jong PHP. Sex Differences in Rheumatoid Arthritis: New Insights From Clinical and Patient-Reported Outcome Perspectives. J Rheumatol. 2025 Jun 1; 52(6): 553-562. doi: 10.3899/jrheum.2024-1258.
Cao M, Li C, Li M, Lu K, Wu C, Wang J, Wei C, Zhao J, Wang Q, Tian X, Tang X, Li M, Zeng X, Gao P. Prevalence and Incidence of Rheumatoid Arthritis in Urban China: A National Population-Based Study. Int J Rheum Dis. 2025 May; 28(5): e70184. doi: 10.1111/1756-185X.70184.
Barragán-Martínez C, Amaya-Amaya J, Pineda-Tamayo R, Mantilla RD, Castellanos-de la Hoz J, Bernal-Macías S, Rojas-Villarraga A, Anaya JM. Gender differences in Latin-American patients with rheumatoid arthritis. Gend Med. 2012 Dec; 9(6): 490-510.e5. doi: 10.1016/j.genm.2012.10.005.
Simón-Campos JA, Padilla-Hernández RO. Correlación de PCR y velocidad de sedimentación globular con la actividad de la artritis reumatoide [Correlation between C reactive protein and erythrosedimentation rate with rheumatoid arthritis disease activity]. Rev Med Inst Mex Seguro Soc. 2008 Nov-Dec; 46(6): 591-6. Spanish. Disponible en: http://www.redalyc.org/articulo.oa?id=457745524003
Domínguez-Horta MDC, Serrano-Díaz A, Hernández-Cedeño M, Martínez-Donato G, Guillén-Nieto G. A peptide derived from HSP60 reduces proinflammatory cytokines and soluble mediators: a therapeutic approach to inflammation. Front Immunol. 2023 Apr 28; 14: 1162739. doi: 10.3389/fimmu.2023.1162739.
Domínguez-Horta MC, Serrano-Díaz A, Hernández-Cedeño M, Martínez-Donato G, Guillén-Nieto G. A peptide derived from HSP60 reduces proinflammatory cytokines and soluble mediators: a therapeutic approach to inflammation. Front Immunol [Internet]. 2023 [citado 15 Dic 2023];14:1162739. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37187739/
Gómez Morejón JA, Herrera Boiset Y, Rodríguez Pérez K, Mora Álvarez LB, Domínguez-Horta M del C, Nodarse Cuní H, Prada Hernández DM et al. Calidad de vida relacionada con la salud en pacientes cubanos con artritis reumatoide refractarios al tratamiento convencional que recibieron terapia con Jusvinza combinado con metotrexate. Rev. cuba. de Reumatol. [Internet]. 20 de noviembre de 2024 [citado 29 de junio de 2025]; 26: e1372. Disponible en: https://revreumatologia.sld.cu/index.php/reumatologia/article/view/1372
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dinorah Marisabel Prada Hernández, Anyel Amelia Suárez Castellanos, Katiuska Rodríguez Pérez, Jorge Alexis Gómez Morejón, Liset Morillo Rodríguez, Hugo Nodarse Cuní , María del Carmen Domínguez-Horta, Silvia Maria Pozo Abreu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
